about
Synthesis and structure-activity relationships of phosphonic arginine mimetics as inhibitors of the M1 and M17 aminopeptidases from Plasmodium falciparumTwo-pronged attack: dual inhibition of Plasmodium falciparum M1 and M17 metalloaminopeptidases by a novel series of hydroxamic acid-based inhibitorsStructure and dynamics of apical membrane antigen 1 from Plasmodium falciparum FVOPotent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactionsStructure and substrate fingerprint of aminopeptidase P from Plasmodium falciparumA new mechanism of allostery in a G protein-coupled receptor dimerDifferential A(1)-adenosine receptor reserve for inhibition of cyclic AMP accumulation and G-protein activation in DDT(1) MF-2 cellsTransformation of poorly water-soluble drugs into lipophilic ionic liquids enhances oral drug exposure from lipid based formulations.Determination of psilocin and psilocybin using flow injection analysis with acidic potassium permanganate and tris(2,2'-bipyridyl)ruthenium(II) chemiluminescence detection respectively.Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptorDesign strategies for bivalent ligands targeting GPCRs.Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor.Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimeticsDesign, Synthesis, and Biological Evaluation of Tetra-Substituted Thiophenes as Inhibitors of p38α MAPK.Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold.Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum aminopeptidases, M1, M17 and M18.A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulationDiscovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand.The role of kinetic context in apparent biased agonism at GPCRs.Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonistThe dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson's disease.Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.The hybrid molecule, VCP746, is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling.Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.Synthesis, Biological Evaluation, and Utility of Fluorescent Ligands Targeting the μ-Opioid Receptor.The synthesis and biological evaluation of multifunctionalised derivatives of noscapine as cytotoxic agents.Effect of linker length and composition on heterobivalent ligand-mediated receptor cross-talk between the A1 adenosine and β2 adrenergic receptors.Synthesis and biological evaluation of N-substituted noscapine analogues.Synthesis and biological evaluation of adenosines with heterobicyclic and polycyclic N(6)-substituents as adenosine A(1) receptor agonists.Role of the Second Extracellular Loop of the Adenosine A1 Receptor on Allosteric Modulator Binding, Signaling, and Cooperativity.Synthesis and evaluation of new N6-substituted adenosine-5'-N-methylcarboxamides as A3 adenosine receptor agonists.VCP746, a novel A1 adenosine receptor biased agonist, reduces hypertrophy in a rat neonatal cardiac myocyte model.Solution NMR characterization of apical membrane antigen 1 and small molecule interactions as a basis for designing new antimalarials.An allosteric modulator of the adenosine A1 receptor improves cardiac function following ischaemia in murine isolated hearts.N-demethylation of N-methyl alkaloids with ferrocene.New irreversible adenosine A(1) antagonists based on FSCPX.A structure-activity analysis of biased agonism at the dopamine D2 receptor.Inter- and intramolecular C-H...pi interactions in morphine bis(1-naphthoate).Efficient N-demethylation of opiate alkaloids using a modified nonclassical Polonovski reaction.New potent and selective A1 adenosine receptor agonists.
P50
Q27684717-6C55D1D7-F515-4C6A-A3EB-23BD52B3D514Q27695695-734F5261-A979-436B-886B-6584A24678DAQ27696056-E11C3350-CAD9-454D-A241-3CC1A5ECF232Q27703729-A9F6D2BA-346C-4007-BE28-AC19477E7F30Q27722348-A41B8E22-7EE1-47C0-B833-2F6723A06D59Q28245604-D60B190A-CE5D-4E93-A8B7-82E706F85D01Q28344419-2CDEA52F-28C6-459B-A234-A86995914D11Q30938737-6600FE48-17B9-4A74-85CE-656114B10304Q34014459-A7C49C86-71CA-4545-8A19-59751E14316DQ34140989-C2AC4830-BAD5-44AD-8B77-E438D8C57313Q34180510-99991EC1-17CA-4142-A4B9-3BB00DBA5961Q34580443-FC451268-6AB2-4E3C-AC44-7700A7181249Q34795759-A1A8FEB0-B719-4A1F-A3F4-9A08EE29C1F0Q35236755-C05A4C63-44E0-40B4-8C27-620EAA2201F4Q35538212-1F62A6B5-46C5-4798-883E-BCD05F4486A4Q35564607-DDFFB468-5456-4D5C-8DAB-9C897BC6C240Q35643821-8DE71F1B-4F0E-4674-9E65-C152D910986FQ35741435-2F5D3ADC-439F-40E6-B020-E188A6B76FBCQ36627558-893F801C-52BF-44E0-B069-3A483B1FE3C5Q37674601-954F4448-74E1-441F-8031-A29A622E5786Q38188614-7CE5BA8F-6F79-44BF-BE73-AACC0ED04F0AQ38209355-1BE10007-BFBC-4D1D-942D-93732976ADE8Q38752171-24D06506-2E08-42DA-AB0C-5C9935C78E06Q38894855-B7066530-9223-4DE0-8147-405A3EB4FFF0Q38935796-F93D482D-5B13-45BC-A374-89698B53881AQ39043075-0F4E2D3F-E5FA-4681-962B-70819A1993A2Q39084286-2CB654FB-904A-4C47-9335-042F38884A67Q39261820-9B1F94A9-E711-4CE7-9D5A-460276F7C9FEQ39333752-1E15A189-813C-43EB-A5F7-52C4DD486A8EQ39341570-220931C6-D437-4595-AE75-71BB1E3C9ED1Q39715745-117731B8-D068-43CE-9467-97AD9853A04EQ40667527-C9959638-34C7-4D8E-95C9-C3230DBD166DQ40820409-CA354582-3086-4699-8B64-95C8787F0560Q42922738-19962ED2-3218-4C30-9FCD-7E31CD5A5B1CQ43003056-6A3BA6BF-6FD3-4699-ABB9-249152F4F7A6Q44173914-5FD5C914-1E93-4B61-9E8F-BAC01A8FF126Q44234043-30FFCCD0-5380-4828-B4BE-C40E8B92896BQ44566149-8D51BB18-AEDB-4003-9ED7-46C2BB7E8BC6Q44680184-2B020165-4835-4219-BCF7-CD4490F8C2FDQ45035604-DB473F8E-12C0-471F-B7D7-2212D4F67D0D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter J. Scammells
@ast
Peter J. Scammells
@en
Peter J. Scammells
@es
Peter J. Scammells
@nl
Peter J. Scammells
@sl
type
label
Peter J. Scammells
@ast
Peter J. Scammells
@en
Peter J. Scammells
@es
Peter J. Scammells
@nl
Peter J. Scammells
@sl
prefLabel
Peter J. Scammells
@ast
Peter J. Scammells
@en
Peter J. Scammells
@es
Peter J. Scammells
@nl
Peter J. Scammells
@sl
P106
P1153
7004375403
P21
P31
P496
0000-0003-2930-895X